Last reviewed · How we verify

NCT05618431: NIPT

Validate Non-invasive Prenatal Tests for the Detection of Chromosomal Abnormalities

Status unknown NA Last updated 6 December 2023
What this trial tests

NA trial testing NIPT in Validation of New Test NIPT in 1,790 participants. Status unknown.

Timeline
1 February 2023
Primary endpoint
1 June 2024
1 June 2024

Quick facts

Lead sponsorCerbaXpert
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposediagnostic
Enrollment1,790
Start date1 February 2023
Primary completion1 June 2024
Estimated completion1 June 2024
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

CerbaXpert

Who can join

Adults 18 to 50, female only, with Validation of New Test NIPT. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study will be conducted on pregnant patients for whom there is a suspicion of a chromosomal abnormality of the fetus. These are patients eligible for non-invasive prenatal screening as part of their usual pregnancy surveillance. This research aims to develop and validate a new method for non-invasive prenatal testing. This prospective collection study will allow the collection of biological samples necessary for the development, testing and validation of these new tests

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of NIPT

Trials testing the same drug.

Other CerbaXpert trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05618431.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing